GlassScriptPhysician profile
Leah K Sutton
NPI 1740979947
$3,331.58
in general payments reported to CMS, 2019-2025
30 companies · $1,302 in 2025
The $1,302 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $402 · 2024: $1,627 · 2025: $1,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,331.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $408.05 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $352.37 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $292.70 | 2023-2025 | |
| Pfizer INC. | $265.76 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $219.71 | 2023-2025 | |
| Exact Sciences Corporation | $158.97 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Regeneron Healthcare Solutions, INC. | $155.53 | 2024-2025 | Dupixent |
| Astellas Pharma US INC | $147.78 | 2023-2025 | Veozah |
| Shionogi INC | $122.07 | 2025 | Fetroja |
| Amgen INC. | $119.16 | 2025 | Repatha, Otezla |
| Insulet Corporation | $118.58 | 2024 | Omnipod |
| Shield Therapeutics INC | $113.20 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $111.33 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $91.97 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.43 | 2024-2025 | Jardiance, Ofev |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $82.98 | 2024 | Prolastin-C Liquid |
| Phathom Pharmaceuticals, INC. | $82.13 | 2024-2025 | Voquezna |
| Dynavax Technologies Corporation | $69.30 | 2023-2025 | Heplisav-B |
| Corcept Therapeutics | $64.05 | 2023-2024 | Korlym |
| Merck Sharp & Dohme LLC | $46.88 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Hologic Sales and Service, LLC | $41.72 | 2024-2025 | Thinprep 2000 Processor, Aptima |
| Mannkind Corporation | $29.87 | 2024 | |
| Daiichi Sankyo INC. | $28.62 | 2024 | Injectafer |
| Radius Health, INC. | $26.13 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.13 | 2025 | |
| Medtronic, INC. | $17.71 | 2023 | Intellis Adaptivestim |
| Organon LLC | $15.44 | 2023 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $15.43 | 2024 | Rexulti |
| Csl Behring | $14.54 | 2025 | Kcentra |
| Dexcom, INC. | $14.04 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.